These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23481700)

  • 1. The human leukocyte antigen-presented ligandome of B lymphocytes.
    Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
    Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
    Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
    Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry.
    Lorente E; Marcilla M; de la Sota PG; Quijada-Freire A; Mir C; López D
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.
    Mylonas R; Beer I; Iseli C; Chong C; Pak HS; Gfeller D; Coukos G; Xenarios I; Müller M; Bassani-Sternberg M
    Mol Cell Proteomics; 2018 Dec; 17(12):2347-2357. PubMed ID: 30171158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes.
    Bremers AJ; van der Burg SH; Kuppen PJ; Kast WM; van de Velde CJ; Melief CJ
    J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):77-85. PubMed ID: 8574469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.
    Kumar P; Boyne C; Brown S; Qureshi A; Thorpe P; Synowsky SA; Shirran S; Powis SJ
    Immunology; 2022 Jun; 166(2):249-264. PubMed ID: 35318648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome.
    Demmers LC; Heck AJR; Wu W
    J Proteome Res; 2019 Apr; 18(4):1634-1643. PubMed ID: 30784271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
    Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
    Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating data for databases--the peptide repertoire of HLA molecules.
    Stevanović S; Lemmel C; Häntschel M; Eberle U
    Novartis Found Symp; 2003; 254():143-55; discussion 155-64, 216-22, 250-2. PubMed ID: 14712936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.
    Gfeller D; Guillaume P; Michaux J; Pak HS; Daniel RT; Racle J; Coukos G; Bassani-Sternberg M
    J Immunol; 2018 Dec; 201(12):3705-3716. PubMed ID: 30429286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
    Chong C; Marino F; Pak H; Racle J; Daniel RT; Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Mol Cell Proteomics; 2018 Mar; 17(3):533-548. PubMed ID: 29242379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.
    Meyer VS; Kastenmuller W; Gasteiger G; Franz-Wachtel M; Lamkemeyer T; Rammensee HG; Stevanovic S; Sigurdardottir D; Drexler I
    J Immunol; 2008 Nov; 181(9):6371-83. PubMed ID: 18941228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.
    Demmers LC; Wu W; Heck AJR
    Mol Cell Proteomics; 2021; 20():100089. PubMed ID: 33933681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.
    Sidney J; Vela JL; Friedrich D; Kolla R; von Herrath M; Wesley JD; Sette A
    BMC Immunol; 2018 Mar; 19(1):12. PubMed ID: 29562882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
    Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
    Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
    Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene and protein sequence features augment HLA class I ligand predictions.
    Bresser K; Nicolet BP; Jeko A; Wu W; Loayza-Puch F; Agami R; Heck AJR; Wolkers MC; Schumacher TN
    Cell Rep; 2024 Jun; 43(6):114325. PubMed ID: 38870014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules.
    Daniel S; Brusic V; Caillat-Zucman S; Petrovsky N; Harrison L; Riganelli D; Sinigaglia F; Gallazzi F; Hammer J; van Endert PM
    J Immunol; 1998 Jul; 161(2):617-24. PubMed ID: 9670935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.